Format

Send to

Choose Destination
Cancer. 2017 May 15;123(6):911-914. doi: 10.1002/cncr.30532. Epub 2017 Jan 17.

Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?

Author information

1
Section of Hematology, Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, Connecticut.
PMID:
28094843
DOI:
10.1002/cncr.30532
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center